

Publications by Rik Schoemaker

Key publications

- Schoemaker R, Fidler M, Laveille C, Wilkins JJ, Hooijmaijers R, Post TM, Trame MN, Xiong Y, Wang W. Performance of the SAEM and FOCEI Algorithms in the Open-Source, Nonlinear Mixed Effect Modeling Tool nlmixr. *CPT Pharmacometrics Syst Pharmacol*. 2019 Dec;8(12):923-930. doi: 10.1002/psp4.12471
<https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/psp4.12471>
 - Schoemaker R, Nayak S, Harnisch LO, Karlsson MO; VISTA-ICH Collaboration. Modeling and simulation of the modified Rankin Scale and National Institutes of Health Stroke Scale neurological endpoints in intracerebral hemorrhage. *J Pharmacokinet Pharmacodyn*. 2019 Oct;46(5):473-484. doi: 10.1007/s10928-019-09653-4
 - Schoemaker R, Wade JR, Stockis A. Extrapolation of Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures. *Clin Pharmacokinet* (2018); 57:843–854
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999174/pdf/40262_2017_Article_597.pdf
 - Schoemaker R, Wade JR, Souza JD, Stockis A. Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures. *Epilepsy res* (2017); Nov; 137:95-100; doi: 10.1016/j.eplepsyres.2017.09.014
 - Schoemaker R, Wade JR, Stockis A. Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures. *J Clin Pharmacol* (2016); 56(12):1591-1602. doi: 10.1002/jcph.761
 - Zoethout RWM, van Gerven JMA, Dumont GJH, Paltansing S, van Burgel ND, van der Linden M, Dahan A, Cohen AF, Schoemaker RC. A comparative study of two methods for attaining constant alcohol levels. *Br J Clin Pharmacol*. 2008; 66 (5), 22–29.
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2661983/pdf/bcp0066-0674.pdf>
 - Kemme MJB, Schoemaker RC, Burggraaf J, van der Linden M, Noordzij M, Moerland M, Klufft C and Cohen AF. Endothelial binding of recombinant tissue plasminogen activator: quantification in vivo using a recirculatory model. *J Pharmacokinet Pharmacodyn* (2003) 30:13-22.
 - Schoemaker RC, van der Vorst MMJ, Ruijs-Dudok van Heel I, Cohen AF, Burggraaf J. Development of an optimal furosemide infusion strategy in infants with modeling and simulation. *Clin Pharmacol Ther* (2002) 72:383-390.
 - Schoemaker RC, Buijs MM, Pijl H, Burggraaf J and Cohen AF. Modeling the influence of Growth Hormone in lipolysis. *J Pharmacokin Pharmacodyn* (2002) 29:2 157-170.
 - Schoemaker RC, van Gerven JMA and Cohen AF. Estimating potency for the Emax-model without attaining maximal effects. *J Pharmacokinet Biopharm* (1998) 26:5 581-593.
- Schoemaker RC and Cohen AF. Estimating impossible curves using NONMEM. *Br J Clin Pharmacol* (1996) 42:283-290.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2042675/pdf/bcp_0423.pdf

PhD Thesis

- H.C. Schoemaker. Modelling repeated measurements in clinical pharmacology; from individual to population and back. PhD Thesis, Leiden University (1999)
https://www.occams.com/assets/pdf/Thesis_RikSchoemaker.pdf

Abstracts at the PAGE conference

- Matthew Fidler, William S. Denney, John Harrold, Richard Hooijmakers, Rik Schoemaker, Max Taubert, Mirjam Trame, Theodoros Papathanasiou, Justin Wilkins. nlmixr2, rxode2 and NONMEM: interchangeable models using babelmixr2 and nonmem2rx. PAGE 31 (2023) Abstr 10313 [www.page-meeting.org/?abstract=10313]
- Rik Schoemaker, Matthew Fidler, Christian Laveille, Justin J. Wilkins, Richard Hooijmaijers, Teun M. Post, Mirjam N. Trame, Yuan Xiong, and Wenping Wang. Performance of the SAEM and FOCEI algorithms in the open-source non-linear mixed effect modelling tool nlmixr. PAGE 28 (2019) Abstr 8978 [www.page-meeting.org/?abstract=8978]
- Janet R Wade, Rik Schoemaker, Lene Alifrangis. Population PK analysis with full and reduced covariate models for Sym004, an antibody mixture targeting EGFR. PAGE 28 (2019) Abstr 8841 [www.page-meeting.org/?abstract=8841]
- Richard Hooijmaijers, Matt Fidler, Rik Schoemaker, Mirjam N. Trame, Wenping Wang, Justin J. Wilkins, Yuan Xiong, Teun M. Post. ShinyMixR: A project-centric R/Shiny run management tool for nlmixr. PAGE 27 (2018) Abstr 8452 [www.page-meeting.org/?abstract=8452]
- Julia Winkler, Kosalaram Goteti, Tonke Van Bragt, Aida Aydemir, Hans Guehring, Rik Schoemaker. Drug-disease model describing the effect of intraarticular injected sprifermin on cartilage thickness measured by magnetic resonance imaging in osteoarthritis patients. PAGE 27 (2018) Abstr 8722 [www.page-meeting.org/?abstract=8722]
- Rik Schoemaker, Matt Fidler, Yuan Xiong, Justin Wilkins, Mirjam Trame, Christian Laveille, Wenping Wang. nlmixr: an open-source package for pharmacometric modelling in R. PAGE 26 (2017) Abstr 7102 [www.page-meeting.org/?abstract=7102]
- Janet R. Wade, Rik Schoemaker, Lene Alifrangis. Population PK analysis of Sym004 and the influence of variations in base model structure on covariate model building. PAGE 26 (2017) Abstr 7119 [www.page-meeting.org/?abstract=7119]
- Rik Schoemaker, Satyaprakash Nayak, William S. Denney, E. Niclas Jonsson, Mats O. Karlsson, Lutz O. Harnisch, on behalf of the VISTA-ICH Collaborators. Modelling and simulation of neurological endpoints (modified Rankin Scale [mRS] and National Institute of Health Stroke Scale [NIHSS]) to aid clinical trial design in intracerebral hemorrhage (ICH). PAGE 25 (2016) Abstr 5905 [www.page-meeting.org/?abstract=5905]
- Julia Winkler, Rik Schoemaker, Armel Stockis. Population pharmacokinetics of lacosamide to support intravenous dose adaptation in children with epilepsy. PAGE 25 (2016) Abstr 6034 [www.page-meeting.org/?abstract=6034]
- Rik Schoemaker, Armel Stockis. Extrapolation of a Brivaracetam Exposure-Response Model from Adults to Children. PAGE 25 (2016) Abstr 5752 [www.page-meeting.org/?abstract=5752]
- Rik Schoemaker, Armel Stockis. PK/PD modeling of brivaracetam in epilepsy using daily seizure counts. PAGE 24 (2015) Abstr 3559 [www.page-meeting.org/?abstract=3559]
- Rik Schoemaker, Armel Stockis. Scaling brivaracetam pharmacokinetic parameters from adult to pediatric epilepsy patients. PAGE 22 (2013) Abstr 2674 [www.page-meeting.org/?abstract=2674]

- Rik Schoemaker, Armel Stockis. Modelling and simulation of spontaneously reported adverse events after administration of lacosamide. PAGE 21 (2012) Abstr 2380 [www.page-meeting.org/?abstract=2380]
- Christian Laveille, Rik Schoemaker, Armel Stockis. Use of an exposure-response model for lacosamide in adults with partial onset seizures to analyze preliminary data from a pediatric trial. PAGE 21 (2012) Abstr 2381 [www.page-meeting.org/?abstract=2381]
- Rik Schoemaker, Jakob Ribbing. Modelling Ordered Categorical Allergic Rhinitis Scores in an Environmental Exposure Unit Study. PAGE 20 (2011) Abstr 2109 [www.page-meeting.org/?abstract=2109]
- Rik Schoemaker, Eric Snoeck, Armel Stockis. Exposure-response modeling of daily seizure counts in focal epilepsy trials. PAGE 19 (2010) Abstr 1726 [www.page-meeting.org/?abstract=1726]
- E. Snoeck, R. Schoemaker, A. Stockis, C. Otoul, M.L. Sargentini-Maier. Levetiracetam exposure-response analysis in children with partial onset seizures. PAGE 17 (2008) Abstr 1403 [www.page-meeting.org/?abstract=1403]
- Strougo, L. Zuurman, C. Roy, J.-L. Piquier, A.F. Cohen, J.M.A. van Gerven, R. Schoemaker. PK and PK/PD Modelling of CNS Effects and Heart Rate After THC Administration in Humans. PAGE 14 (2005) Abstr 706 [www.page-meeting.org/?abstract=706]
- Rik C. Schoemaker, Madelon M. Buijs, Hanno Pijl, Adam F. Cohen. Integrated mathematical modeling of lipolysis. PAGE 10 (2001) Abstr 236 [www.page-meeting.org/?abstract=236]
- Rik C. Schoemaker, I. Ruys-Dudok van Heel, M.M.J. van der Vorst, J.E. Kist-van Holthe tot Echten, J. Burggraaf, A.F. Cohen. In Search of an Optimal Furosemide Infusion Strategy in Children after Cardiac Surgery Using Modelling and Simulation. PAGE 9 (2000) Abstr 87 [www.page-meeting.org/?abstract=87]
- M. de Hoog, A.A.T.M.M. Vinks, R.C. Schoemaker, J.N. van den Anker. Pharmacokinetic modeling of tobramycin in neonates: a comparison of NONMEM and NPEM2. PAGE 9 (2000) Abstr 125 [www.page-meeting.org/?abstract=125]
- MO Karlsson, RC Schoemaker, B Kemp, A Cohen, J van Gerven, M Danhof. A Pharmacodynamic Markov Mixed Effect Model for Temazepam Effect on Sleep. PAGE 8 (1999) Abstr 135 [www.page-meeting.org/?abstract=135]
- Rik C. Schoemaker, Joop M.A. van Gerven, Adam F. Cohen. Estimating potency for the Emax-model without attaining maximal effects. PAGE 7 (1998) Abstr 278 [www.page-meeting.org/?abstract=278]
- R.C. Schoemaker, J. Burggraaf, A.F. Cohen. Assessment Of Liver Blood Flow Using A Continuous Infusion Of A Drug With High Hepatic Clearance. PAGE 5 (1996) Abstr 554 [www.page-meeting.org/?abstract=554]
- Rik Schoemaker, Adam Cohen. Estimation of Kinetic/Dynamic Curves With Insufficient Information for Each Individual Using Non-Linear Mixed Effect Modelling. PAGE 4 (1995) Abstr 639 [www.page-meeting.org/?abstract=639]

All publications (full papers only)

- 184 Fidler M, Hooijmaijers R, Schoemaker R, Wilkins JJ, Xiong Y, and Wang W. R and nlmixr as a gateway between statistics and pharmacometrics. *CPT Pharmacometrics Syst Pharmacol*. 2021 Apr;10(4):283-285. doi: 10.1002/psp4.12618.
- 183 Zhu R, Owen R, Wilkins J, Schoemaker R, Tian X, Gautier A, She G, Vadhavkar S, Cheu M, Wong K, Omachi TA, Putnam WS, and Quartino AL. Pharmacokinetics and exposure-efficacy relationships of omalizumab in patients with nasal polyps. *Pulmonary Pharmacology & Therapeutics*, 2021 December, 71, <https://doi.org/10.1016/j.pupt.2021.102080>.
- 182 Alifrangis L, Schoemaker R, Skartved NJ, Hald R, Montagut C, Kopetz S, Tabernero J, Kragh M, Wade JR. Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors. *J Pharmacokinet Pharmacodyn*. 2020 Feb;47(1):5-18. doi: 10.1007/s10928-019-09663-2. Epub 2019 Nov 2. PMID: 31679083.
- 181 Schoemaker R, Fidler M, Laveille C, Wilkins JJ, Hooijmaijers R, Post TM, Trame MN, Xiong Y, Wang W. Performance of the SAEM and FOCEI Algorithms in the Open-Source, Nonlinear Mixed Effect Modeling Tool nlmixr. *CPT Pharmacometrics Syst Pharmacol*. 2019 Dec;8(12):923-930. doi: 10.1002/psp4.12471. Epub 2019 Nov 18. PMID: 31654482; PMCID: PMC6930853.
- 180 Schoemaker R, Nayak S, Harnisch LO, Karlsson MO; VISTA-ICH Collaboration. Modeling and simulation of the modified Rankin Scale and National Institutes of Health Stroke Scale neurological endpoints in intracerebral hemorrhage. *J Pharmacokinet Pharmacodyn*. 2019 Oct;46(5):473-484. doi: 10.1007/s10928-019-09653-4. Epub 2019 Aug 29. PMID: 31468269.
- 179 Fidler M, Wilkins JJ, Hooijmaijers R, Post TM, Schoemaker R, Trame MN, Xiong Y, Wang W. Nonlinear Mixed-Effects Model Development and Simulation Using nlmixr and Related R Open-Source Packages. *CPT Pharmacometrics Syst Pharmacol*. 2019 Sep;8(9):621-633. doi: 10.1002/psp4.12445. Epub 2019 Jul 16. PMID: 31207186; PMCID: PMC6765694.
- 178 Winkler J, Schoemaker R, Stockis A. Population Pharmacokinetics of Adjunctive Lacosamide in Pediatric Patients With Epilepsy. *J Clin Pharmacol*. 2019 Apr;59(4):541-547. doi: 10.1002/jcph.1340. Epub 2018 Nov 14. PMID: 30427550.
- 177 Winkler J, Schoemaker R, Stockis A. Modeling and simulation for the evaluation of dose adaptation rules of intravenous lacosamide in children. *Epilepsy Res*. 2019 Jan;149:13-16. doi: 10.1016/j.eplepsyres.2018.10.011. Epub 2018 Oct 26. PMID: 30415109.
- 176 Schoemaker R, Wade JR, Souza JD, Stockis A. Evaluation of brivaracetam efficacy as monotherapy in adult patients with focal seizures. *Epilepsy res (2017)*; Nov; 137:95-100; doi: 10.1016/j.eplepsyres.2017.09.014
- 175 Schoemaker R, Wade JR, Stockis A. Extrapolation of Brivaracetam Exposure-Response Model from Adults to Children with Focal Seizures. *Clin Pharmacokinet (2017)*; Sep 7; [Epub ahead of print], doi: 10.1007/s40262-017-0597-2
- 174 Schoemaker R, Wade JR, Stockis A. Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years. *Eur J Clin Pharmacol (2017)*; 73: 727-733; doi: 10.1007/s00228-017-2230-6. Epub 2017 Mar 9
- 173 Schoemaker R, Wade JR, Stockis A. Brivaracetam Population Pharmacokinetics and Exposure-Response Modeling in Adult Subjects With Partial-Onset Seizures. *J Clin Pharmacol (2016)*; 56(12):1591-1602. doi: 10.1002/jcph.761

- 172 de Haas SL, Zoethout RWM, Van Dyck K, De Smet M, Rosen LB, Murphy MG, Gottesdiener KM, Schoemaker RC, Cohen AF and van Gerven JMA. The effects of TPA023, a GABA α 2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol. *J Psychopharmacol* published online 2 September 2011.
- 171 Zoethout RW, Iannone R, Bloem BR, Palcza J, Murphy G, Chodakewitz J, Buntinx A, Gottesdiener K, Marsilio S, Rosen L, van Dyck K, Louis ED, Cohen AF, Schoemaker RC, Tokita S, Sato N, Koblan KS, Hargreaves RH, Renger JJ, van Gerven JM. The effects of a novel histamine-3 receptor inverse agonist on essential tremor in comparison to stable levels of alcohol. *J Psychopharmacol*. 2011 Feb 24. [Epub ahead of print]
- 170 Liem-Moolenaar M, de Boer P, Timmers M, Schoemaker RC, van Hasselt JGC, Schmidt S & van Gerven JMA. Pharmacokinetic–pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects. *British Journal of Clinical Pharmacology*. 2011; 71 (6), 886–898.
- 169 de Haas S, Schoemaker R, van Gerven J, Hoefer P, Cohen A, Dingemans J. Pharmacokinetics, pharmacodynamics and the pharmacokinetic/pharmacodynamic relationship of zolpidem in healthy subjects. *J Psychopharmacol*. 2009 Jul 31. [Epub ahead of print]
- 168 Zuurman L, Roy C, Schoemaker R, Amatsaleh A, Guimaeres L, Piquier J, Cohen A, van Gerven J. Inhibition of THC-induced effects on the central nervous system and heart rate by a novel CB1 receptor antagonist AVE1625. *J Psychopharmacol*. 2010; 24(3):363-71
- 167 Hoefer P, de Haas S, Winkler J, Schoemaker RC, Chiossi E, van Gerven J and Dingemans J. Orexin Receptor Antagonism, a New Sleep-Promoting Paradigm: An Ascending Single-Dose Study With Almorexant. *Clinical pharmacology & Therapeutics*. 2010; 87(5):593-600.
- 166 Dumont G, Kramers C, Sweep F, Willemsen J, Touw D, Schoemaker R, van Gerven J, Buitelaar J, Verkes R. Ethanol co-administration moderates 3,4-methylenedioxymethamphetamine effects on human physiology. *J Psychopharmacol*. 2010; 24(2):165-74.
- 165 Dumont G, Schoemaker R, Touw D, Sweep F, Buitelaar J, van Gerven J, Verkes R. Acute psychomotor effects of MDMA and ethanol (co-) administration over time in healthy volunteers. *J Psychopharmacol*. 2010; 24(2):155-64.
- 164 van Haarst AD, Dijkmans A, Weimann HJ, Kemme MJ, Bosch JJ, Schoemaker RC, Cohen AF, Burggraaf J. Clinically Important Interaction Between Tedisamil and Verapamil. *J Clin Pharmacol*. 2009; 49(5):560-567.
- 163 Wirtz P, Verschuuren J, van Dijk J, de Kam M, Schoemaker R, van Hasselt J, Titulaer M, Tjaden U, den Hartigh J, van Gerven J. Efficacy of 3,4-Diaminopyridine and Pyridostigmine in the Treatment of Lambert-Eaton Myasthenic Syndrome: A Randomized, Double-Blind, Placebo-Controlled, Crossover Study. *Clin Pharmacol Ther*. 2009;86(1):44-8.
- 162 Zoethout RW, Schoemaker RC, Zuurman L, van Pelt H, Dahan A, Cohen AF, van Gerven JM. Central nervous system effects of alcohol at a pseudo-steady-state concentration using alcohol clamping in healthy volunteers. *Br J Clin Pharmacol*. 2009;68(4):524-34.
- 161 Zoethout RWM, van Gerven JMA, Dumont GJH, Paltansing S, van Burgel ND, van der Linden M, Dahan A, Cohen AF, Schoemaker RC. A comparative study of two methods for attaining constant alcohol levels. *British Journal of Clinical Pharmacology*. 2008; 66 (5), 22–29.
- 160 Liem-Moolenaar M, Gray F, de Visser S, Franson K, Schoemaker R, Schmitt J, Cohen A, van Gerven J. Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol. *J Psychopharmacol*. *J Psychopharmacol*. 2010;24(1):73-82

- 159 Willemze AJ, Cremers SC, Schoemaker RC, Lankester AC, den Hartigh J, Burggraaf J, Vossen JM. Ciclosporin kinetics in children after stem cell transplantation. *Br J Clin Pharmacol*. 2008; 66(4):539-545.
- 158 Zuurman L, Roy C, Schoemaker RC, Hazekamp A, den Hartigh J, Bender JC, Verpoorte R, Pinquier JL, Cohen AF, van Gerven JM. Effect of intrapulmonary tetrahydrocannabinol administration in humans. *J Psychopharmacol*. 2008; 22(7):707-716.
- 157 Strougo A, Zuurman L, Roy C, Pinquier JL, van Gerven JM, Cohen AF, Schoemaker RC. Modelling of the concentration-effect relationship of THC on central nervous system parameters and heart rate - insight into its mechanisms of action and a tool for clinical research and development of cannabinoids. *J Psychopharmacol*. 2008; 22(7): 717-726.
- 156 Boot JD, De Haas SL, Van Gerven JM, De Smet M, Leathem T, Wagner J, Denker A, Miller D, Van Doorn MB, Schoemaker RC, Cohen AF, Diamant Z. MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers. *Pulm Pharmacol Ther*. 2008;21(3):573-7.
- 155 Broeyer FJ, Osanto S, Ritsema van Eck HJ, van Steijn AQ, Ballieux BE, Schoemaker RC, Cohen AF, Burggraaf J. Evaluation of biomarkers for cardiotoxicity of anthracyclin-based chemotherapy. *J Cancer Res Clin Oncol*. 2008 Sep;134(9):961-8.
- 154 Eustatia-Rutten CF, Corssmit EP, Heemstra KA, Smit JW, Schoemaker RC, Romijn JA, Burggraaf J. Autonomic nervous system function in chronic exogenous subclinical thyrotoxicosis and the effect of restoring euthyroidism. *J Clin Endocrinol Metab*. 2008 Jul;93(7):2835-41.
- 153 Smarius LJCA, Jacobs GE, Hoeberechts-Lefrandt DHM, de Kam ML, van der Post JP, de Rijk R, van Pelt J, Schoemaker RC, Zitman FG, van Gerven JMA, and Gijsman HJ. Pharmacology of rising oral doses of 5-hydroxytryptophan with carbidopa. *J Psychopharmacol* 2008 22: 426-433.
- 152 de Haas SL, de Visser SJ, van der Post JP, Schoemaker RC, van Dyck K, Murphy MG, de Smet M, Vessey LK, Ramakrishnan R, Xue L, Cohen AF, van Gerven JMA. Pharmacodynamic and pharmacokinetic effects of MK-0343, a GABA α 2,3 subtype selective agonist, compared to lorazepam and placebo in healthy male volunteers. *Journal of Psychopharmacology* 22(1) (2008) 24–32.
- 151 Broeyer JF, B. E. van Aken, J. Suzuki, M. J. B. Kemme, H. C. Schoemaker, A. F. Cohen, Y. Mizushima, J. Burggraaf. The pharmacokinetics and effects of a long-acting preparation of superoxide dismutase (PC-SOD) in man. *British Journal of Clinical Pharmacology*. 2008; 65 (1), 22–29.
- 150 de Haas SL, de Visser SJ, van der Post JP, de Smet M, Schoemaker RC, Rijnbeek B, Cohen AF, Vega JM, Agrawal NG, Goel TV, Simpson RC, Pearson LK, Li S, Hesney M, Murphy MG, van Gerven JM. Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers. *J Psychopharmacol*. 2007 Jun;21(4):374-83.
- 149 van Doorn M, Kemme M, Ouwens M, van Hoogdalem EJ, Jones R, Romijn H, de Kam M, Schoemaker R, Burggraaf K, Cohen A. Evaluation of proinflammatory cytokines and inflammation markers as biomarkers for the action of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers. *Br J Clin Pharmacol*. 2006 Oct;62(4):391-402.
- 148 van Doorn MB, Espirito Santo SM, Meijer P, Kamerling IM, Schoemaker RC, Dirsch V, Vollmar A, Haffner T, Gebhardt R, Cohen AF, Princen HM, Burggraaf J. Effect of garlic powder on C-reactive protein and plasma lipids in overweight and smoking subjects. *Am J Clin Nutr*. 2006 Dec;84(6):1324-9.

- 147 Rad M, Hümpel M, Schaefer O, Schoemaker RC, Schleuning W-D, Cohen AF, Burggraaf J. Pharmacokinetics and systemic endocrine effects of the phyto-oestrogen 8-prenylnaringenin after single oral doses to postmenopausal women. *British Journal of Clinical Pharmacology* 2006, 62 (3), 288–296.
- 146 Levitt DG and Schoemaker RC. Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat. *BMC Clinical Pharmacology* 2006, 6:1 (<http://www.biomedcentral.com/1472-6904/6/1>).
- 145 Boot JD, Tarasevych S, Sterk PJ, Schoemaker RC, Wang L, Amin D, Cohen AF, Diamant Z. Reversal of the late asthmatic response increases exhaled nitric oxide. *Respir Med.* 2005 Dec; 99(12):1591-4.
- 144 Scholten EM, Cremers SC, Schoemaker RC, Rowshani AT, van Kan EJ, den Hartigh J, Paul LC, de Fijter JW. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. *Kidney Int.* 2005 Jun;67(6):2440-7.
- 143 Cremers S, Schoemaker R, Scholten E, den Hartigh J, König-Quartel J, van Kan E, Paul L, de Fijter J. Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling. *Br J Clin Pharmacol.* 2005 Sep;60(3):249-56.
- 142 van Doorn MB, Burggraaf J, van Dam T, Eerenberg A, Levi M, Hack CE, Schoemaker RC, Cohen AF, Nuijens J. A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. *J Allergy Clin Immunol.* 2005 Oct;116(4):876-83.
- 141 Jazet IM, Pijl H, Frolich M, Schoemaker RC, Meinders AE. Factors predicting the blood glucose lowering effect of a 30-day very low calorie diet in obese Type 2 diabetic patients. *Diabet Med.* 2005 Jan;22(1):52-5.
- 140 Cohen J, Burggraaf J, Schoemaker RC, Sterk PJ, Cohen AF, Diamant Z. Relationship between airway responsiveness to neurokinin A and methacholine in asthma. *Pulm Pharmacol Ther.* 2005;18(3):171-6.
- 139 Bonnet RM, Mattie H, de Laat JA, Schoemaker HC, Frijns JH. Clinical ototoxicity of teicoplanin. *Ann Otol Rhinol Laryngol.* (2004) 113(4):310-312.
- 138 Kamerling IM, van Haarst AD, Burggraaf J, Schoemaker RC, de Kam ML, Heinzerling H, Cohen AF, Masclee AA. Effects of a nonpeptide motilin receptor antagonist on proximal gastric motor function. *Br J Clin Pharmacol.* (2004) 57(4):393-401.
- 137 Zwaveling J, Bubbers S, van Meurs AH, Schoemaker RC, van Heel IR, Vermeij P, Burggraaf J. Pharmacokinetics of rectal tramadol in postoperative paediatric patients. *Br J Anaesth.* (2004) 93:224-227.
- 136 van der Post JP, de Visser SJ, Schoemaker RC, Cohen AF, van Gerven JM. Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients. *J Psychopharmacol.* (2004)18:221-227.
- 135 Litjens NH, Burggraaf J, van Strijen E, van Gulpen C, Mattie H, Schoemaker RC, van Dissel JT, Thio HB, Nibbering PH. Pharmacokinetics of oral fumarates in healthy subjects. *Br J Clin Pharmacol.* (2004) 58:429-432.
- 134 I.M. Kamerling, J. Burggraaf, A.D. van Haarst, M.F. Oppenhuizen Duinker, H.C. Schoemaker, I. Biemond, R. Jones, H. Heinzerling, A.F. Cohen and A.A. Masclee. The effect of motilin on the rectum in healthy volunteers. *Br J Clin Pharmacol* (2003) 55:6 538-543.

- 133 M.S.M. Pieters, A.F. van Steveninck, R.C. Schoemaker, J.M. Kroon, J.M.A. van Gerven and A.F. Cohen. The psychomotor effects of carbamazepine in epileptic patients and healthy volunteers. *Journal of Psychopharmacology* (2003) 17(3): 269-272.
- 132 I.M.C. Kamerling, A.D. van Haarst, J. Burggraaf, R.C. Schoemaker, I. Biemond, H. Heinzerling, R. Jones, A.F. Cohen and A.A.M. Masclee. Motilin effects on the proximal stomach in patients with functional dyspepsia and healthy volunteers. *Am J Physiol Gastrointest Liver Physiol* (2003) 284:5 G776-781.
- 131 M.J.B. Kemme, J. Burggraaf, R.C. Schoemaker, A.F. Cohen, C. Kluft, S. Chia, D.J. Webb and D.E. Newby. Local tissue factor pathway inhibitor release in the human forearm. *Thromb Haemost* (2003) 89:3 438-445.
- 130 M.J.B. Kemme, R.C. Schoemaker, J. Burggraaf, M. van der Linden, M. Noordzij, M. Moerland, C. Kluft and A.F. Cohen. Endothelial binding of recombinant tissue plasminogen activator: quantification in vivo using a recirculatory model. *J Pharmacokinet Pharmacodyn* (2003) 30:1 3-22.
- 129 S.C.L.M. Cremers, E.M. Scholten, R.C. Schoemaker, E.G.W.M. Lentjes, P. Vermeij, L.C. Paul, J. den Hartigh and J.W. de Fijter. A compartmental pharmacokinetic model of cyclosporin and its predictive performance after Bayesian estimation in kidney and simultaneous pancreas-kidney transplant recipients. *Nephrol Dial Transplant* (2003) 18:6 1201-1208.
- 128 M.J.B. Kemme, J.P. vd Post, R.C. Schoemaker, M. Straub, A.F. Cohen and J.M.A. van Gerven. Central nervous system effects of moxonidine experimental sustained release formulation in patients with mild to moderate essential hypertension. *Br J Clin Pharmacol* (2003) 55:6 518-525.
- 127 H.J. Gijsman, J.M.A. van Gerven, M.L. de Kam, R.C. Schoemaker, M.S.M. Pieters, M. Weemaes, R. de Rijk, J. van der Post and A.F. Cohen. Placebo-controlled comparison of three dose-regimens of 5-hydroxytryptophan challenge test in healthy volunteers. *J Clin Psychopharmacol* (2002) 22:2 183-189.
- 126 M. de Hoog, J.W. Mouton, R.C. Schoemaker, C.M. Verduin and J.N. van den Anker. Extended-interval dosing of tobramycin in neonates: implications for therapeutic drug monitoring. *Clin Pharmacol Ther* (2002) 71:5 349-358.
- 125 J. van der Post, M.T. Schram, R.C. Schoemaker, M.S.M. Pieters, E. Fuseau, A. Pereira, S. Baggen, A.F. Cohen and J.M.A. van Gerven. CNS effects of sumatriptan and rizatriptan in healthy female volunteers. *Cephalalgia* (2002) 22:4 271-281.
- 124 M. de Hoog, R.C. Schoemaker, J.N. van den Anker and A.A.Vinks. NONMEM and NPEM2 population modeling: a comparison using tobramycin data in neonates. *Ther Drug Monit* (2002) 24:3 359-365.
- 123 R.A. Faaij, J. Burggraaf, R.C. Schoemaker, R.G. Van Amsterdam and A.F. Cohen. Absence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin. *Br J Clin Pharmacol* (2002) 54:3 304-308.
- 122 O. Weijtens, R.C. Schoemaker, F.P. Romijn, A.F. Cohen, E.G. Lentjes and J.C. Van Meurs. Intraocular penetration and systemic absorption after topical application of dexamethasone disodium phosphate. *Ophthalmology* (2002) 109:10 1887-1891.
- 121 H.J. Gijsman, J.M.A. Van Gerven, R.J. Verkes, R.C. Schoemaker, M.S.M. Pieters, E.J. Pennings, T.J. Hessing and A.F. Cohen. Saccadic peak velocity and EEG as end-points for a serotonergic challenge test. *Hum Psychopharmacol* (2002) 17:2 83-89.

- 120 M.J.B. Kemme, J. Burggraaf, R.C. Schoemaker, C. Kluft and A.F. Cohen. Quantification of heparin-induced TFPI release: a maximum release at low heparin dose. *Br J Clin Pharmacol* (2002) 54:627-634.
- 119 R. C. Schoemaker, M. M. J. van der Vorst, I. Ruijs-Dudok van Heel, A. F. Cohen, J. Burggraaf. Development of an optimal furosemide infusion strategy in infants with modeling and simulation. *Clin Pharmacol Ther* (2002) 72:383-390.
- 118 C. Ollier, R.A. Faaij, A. Santoni, T. Duvauchelle, P.M.M. van Haard, R.C. Schoemaker, A.F. Cohen, R. de Greef and J. Burggraaf. Absence of interaction of fondaparinux sodium with aspirin and piroxicam in healthy male volunteers. *Clin Pharmacokinet* (2002) 41 Suppl. 2:31-37.
- 117 R.A. Faaij, J. Burggraaf, R.C. Schoemaker, R. de Greef and A.F. Cohen. The synthetic pentasaccharide fondaparinux sodium does not interact with oral warfarin. *Clin Pharmacokinet* (2002) 41 Suppl. 2:27-29.
- 116 S.J. de Visser, J.P. van der Post, L. Nanhekhan, R.C. Schoemaker, A.F. Cohen and J.M.A. van Gerven. Concentration-effect relationship of two rilmenidine single-dose infusion rates in hypertensive patients. *Clin Pharmacol Ther* (2002) 72:419-428.
- 115 M.M. Buijs, J. Burggraaf, J.G. Langendonk, R.C. Schoemaker, M. Fröhlich, J-W. Arndt, A.F. Cohen, J.A. Romijn, M.T. Ackermans, H.P. Sauerwein, A.E. Meinders and H. Pijl. Hyposomatotropism blunts lipolysis in abdominally obese women. *J Clin Endocrinol Metab* (2002) 87:3851-3858.
- 114 R.C. Schoemaker, M.M. Buijs, H. Pijl, J. Burggraaf and A.F. Cohen. Modeling the influence of Growth Hormone in lipolysis. *J Pharmacokin Pharmacodyn* (2002) 29:2 157-170.
- 113 S. Cremers, R. Schoemaker, R. Bredius, J. den Hartigh, L. Ball, I. Twiss, P. Vermeij and J. Vossen. Pharmacokinetics of intravenous busulfan in children prior to stem cell transplantation. *Br J Clin Pharmacol* (2002) 53:386-389.
- 112 I.M.C. Kamerling, A.D. van Haarst, J. Burggraaf, H.C. Schoemaker, I. Biemond, R. Jones, A.F. Cohen and A.A.M. Masclee. Dose-related effects of motilin on proximal gastrointestinal motility. *Aliment Pharmacol Ther* (2002) 16:129-135.
- 111 I.M. Twiss, J. Burggraaf, R.C. Schoemaker, R.M. van Elburg, J. den Hartigh, A.F. Cohen and P. Vermeij. The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate. *Clin Pharmacol Ther* (2001) 69:6 431-7
- 110 S.J. de Visser, J.M.A. van Gerven, H.C. Schoemaker and A.F. Cohen. Concentration-effect relationships of two infusion rates of the imidazoline antihypertensive agent rilmenidine for blood pressure and development of side-effects in healthy subjects. *Br J Clin Pharmacol* (2001) 51:423-428.
- 109 S.J. de Visser, P.W. Vis, J.M.A. van Gerven, H.C. Schoemaker and A.F. Cohen. Comparison of oral and oral sustained-release rilmenidine in healthy volunteers and correlation with in vitro sustained-release properties. (2001) *Clin Drug Invest* 21:579-586.
- 108 M. Kemme, R.A. Faaij, H.C. Schoemaker, C. Kluft, P. Meijer, A.F. Cohen and J. Burggraaf. Disagreement between bedside and laboratory activated partial thromboplastin time and international normalized ratio for various novel anticoagulants. *Blood Coagulation and Fibrinolysis* (2001) 12:583-591.
- 107 J. Burggraaf, J.H. Tulen, S. Lalezari, R.C. Schoemaker, P.H. de Meyer, A.E. Meinders, A.F. Cohen and H. Pijl. Sympathovagal imbalance in hyperthyroidism *Am.J.Physiol Endocrinol.Metab* (2001) 281:E190-E195.

- 106 J. Burggraaf, R.G.J. Westendorp, in 't Veen, H.C. Schoemaker, P.J. Sterk, A.F. Cohen and G.J. Blauw. Cardiovascular side effects of inhaled salbutamol in asthmatic patients who are hypoxic. *Thorax* (2001) 56:567-569.
- 105 H. Pijl, P.H.E.M. de Meijert, J. Langius, C.I.G.M. Coenegracht, A.H.M. van den Berk, P.K. Chandie Shaw, H. Boom, R.C. Schoemaker, A.F. Cohen, J. Burggraaf and A.E. Meinders. Food choice in hyperthyroidism: potential influence of the autonomic nervous system and brain serotonin precursor availability. *Journal of Clinical Endocrinology and Metabolism* (2001) 86:5848-5853.
- 104 M.J. Kemme, J. Burggraaf, R.C. Schoemaker and A.F. Cohen. No Influence of Acute Hypertriglyceridemia on Plasma t-PA in Healthy Male Volunteers. *Thromb Res* (2001) 103:9-16.
- 103 M.M. van der Vorst, I. Ruys-Dudok van Heel, J.E. Kist-van Holthe, J. den Hartigh, R.C. Schoemaker, A.F. Cohen and J Burggraaf . Continuous intravenous furosemide in haemodynamically unstable children after cardiac surgery. *Intensive Care Med* (2001) 27:711-5.
- 102 M. Kreilgaard, M.J.B. Kemme, J. Burggraaf, R.C. Schoemaker and A.F. Cohen. Influence of a microemulsion vehicle on cutaneous bioequivalence of a lipophilic model drug assessed by microdialysis and pharmacodynamics. *Pharmaceutical Research* (2001) 18:593-599.
- 101 R.A. Faaij, J.M.T. van Griensven, R.C. Schoemaker, T. Goggin, A. Guenzi, J.M. Kroon, J. Burggraaf and A.F. Cohen. The effect of warfarin on the pharmacokinetics and pharmacodynamics of napsagatran in healthy male volunteers. *Eur J Clin Pharmacol* (2001) 57:25-29.
- 100 R.J. Verkes H.J. Gijsman, M.S.M. Pieters, R.C. Schoemaker, S. de Visser, M. Kuijpers, E.J.M. Pennings, D. de Bruin, G. van de Wijngaart, J.M.A. van Gerven and A.F. Cohen. Cognitive performance and serotonergic function in users of ecstasy. *Psychopharmacology* (2001) 153:196-202.
- 99 J.G. Langendonk, J.D. Veldhuis, J. Burggraaf, R.C. Schoemaker, A.F. Cohen, A.E. Meinders and H. Pijl. Estimation of growth hormone secretion rate: impact of kinetic assumptions intrinsic to the analytical approach. *Am J Physiol Regulatory Integrative Comp Physiol* (2001) 280:R225-R232.
- 98 J. Burggraaf, R.C. Schoemaker, E.G.W.M. Lentjes and A.F. Cohen. Sorbitol as a marker for drug-induced decreases of variable duration in liver blood flow in healthy volunteers. *European Journal of Pharmaceutical Sciences* (2000) 12:133-139.
- 97 M.J.B. Kemme, J. Burggraaf, R.C. Schoemaker, A.F. Cohen and G.J. Blauw. No evidence for functional involvement of 5-HT_{2b} receptors in serotonin-induced vasodilatation in the human forearm. *Journal of Cardiovascular Pharmacology* (2000) 36:699-703.
- 96 O. Weijtens, R.C. Schoemaker, E.G.W.M. Lentjes, F.P.H.T.M. Romijn, A.F. Cohen and J.C. van Meurs. Dexamethasone concentration in subretinal fluid after a subconjunctival injection, a peribulbar injection, or an oral dose. *Ophthalmology* (2000) 107:1932-1938.
- 95 J. Burggraaf, M.J.B. Kemme, L.M. Muller, R.C. Schoemaker and A.F. Cohen. The influence of the hand circulation on the assessment of venous distensibility of the human forearm with venous occlusion plethysmography. *Br J Clin Pharmacol* (2000) 50: 621-623.
- 94 A. de Roode, J.M.A. van Gerven, R.C. Schoemaker, F.H.M. Engbers, W. Olieman, J.R. Kroon, A.F. Cohen and J.G. Bovill. A comparison of the effects of propofol and midazolam on memory during two levels of sedation by using target-controlled infusion. *Anest Analg* (2000) 91 1056-1061.

- 93 M.O. Karlsson, R.C. Schoemaker, B. Kemp, A.F. Cohen, MD, J.M.A. van Gerven, B. Tuk, C.C. Peck and M. Danhof. A pharmacodynamic Markov mixed-effect model for the effect of temazepam on sleep. *Clin Pharmacol Ther* (2000) 68:2 175-188.
- 92 M. de Hoog, R.C. Schoemaker, J.W. Mouton and J.N. van den Anker. Vancomycin population pharmacokinetics in neonates. *Clin Pharmacol Ther* (2000) 67:4 360-367.
- 91 M.J. Kemme, J. Burggraaf, R.C. Schoemaker, S. Paulson, A. Karim, E.G. Lentjes, A. Childs, R.A. Braeckman and A.f. Cohen. The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor. *Clin Pharmacol Ther* (2000) 67:5 504-511.
- 90 H.J. Gijsman, R.J. Verkes, J.C.M. Schouten-Verhagen, R.C. Schoemaker, J.M.A. Van Gerven, R.H. De Rijk and G.M.J. Van Kempen. Estimation of plasma serotonin using isopycnic centrifugation. *Hum. Psychopharmacol. Clin. Exper.* (2000)15:417-421.
- 89 R.A. Faaij, J.M. van Gerven, I. Jolivet-Landreau, A.A. Masclee, E.M. Vendrig, R.C. Schoemaker, L.D. Jacobs, and A.F. Cohen. Onset of action during on-demand treatment with maalox suspension or low-dose ranitidine for heartburn. *Aliment Pharmacol Ther* (1999) 13:12 1605-1610.
- 88 P.P. Schiphorst, P.C. Chang, N. Clar, R.C. Schoemaker, and S. Osanto. Pharmacokinetics of interleukin-2 in two anephric patients with metastatic renal cell cancer. *Ann. Oncol.* (1999) 10:1381-1383.
- 87 P.H. van der Graaf and R.C. Schoemaker. Analysis of asymmetry of agonist concentration-effect curves. *J. Pharm and Toxicol.* (1999) 41: 107-115.
- 86 R.A. Faaij, N. Srivastava, J.M.T. van Griensven, H.C. Schoemaker, C. Kluft, J. Burggraaf and A.F. Cohen. The oral bioavailability of pentosan polysulphate sodium in healthy volunteers. *Eur. J. Clin. Pharmacol.* (1999) 54:929-935.
- 85 J.G. Langendonk, A.E. Meinders, J. Burggraaf, M. Fröhlich, C.A.M. Roelen, R.C. Schoemaker, A.F. Cohen and H. Pijl. Influence of obesity and body fat distribution on growth hormone kinetics in humans. *Am. J. Physiol.* 277 (Endocrinol. Metab. 40) (1999) E:824-829.
- 84 O. Weijtens, E.J. Feron, R.C. Schoemaker, A.F. Cohen, E.G.W.M. Lentjes, F.P.H.T.M. Romijn and J.C. van Meurs. High concentrations of dexamethasone in aqueous and vitreous after subconjunctival injection. *Am J Ophthalmol* (1999) 128:192-197.
- 83 G. Voortman, J. Van der Post, R.C. Schoemaker, J.M.A. Van Gerven. Bioequivalence of subcutaneous injections of recombinant follicle stimulating hormone (Puregon) by pen-injector and syringe. *Hum Reprod* (1999);14(7):1698-1702.
- 82 D.C. Cath, H.J. Gijsman, R.C. Schoemaker, J.M.T. van Griensven, N. Troost, G.M.J. van Kempen and A.F. Cohen. The effect of m-CPP on tics and obsessive-compulsive phenomena in Gilles de la Tourette syndrome. *Psychopharmacology* (1999) 144:137-143.
- 81 A.L. Van Steveninck, B.N.M. Van Berckel, R.C. Schoemaker, D.D. Breimer, J.M.A. Van Gerven and A.F. Cohen. The sensitivity of pharmacodynamic tests for central nervous system effects of drugs on the effects of sleep deprivation. *J Psychopharmacol* (1999) 3:10-17.
- 80 H.C. Schoemaker. Modelling repeated measurements in clinical pharmacology; from individual to population and back. PhD Thesis, Leiden University (1999).
- 79 R. C. Schoemaker, J.M.A. van Gerven and A. F. Cohen. Estimating potency for the Emax-model without attaining maximal effects. *J Pharmacokinet Biopharm* (1998) 26:5 581-593.

- 78 J. Burggraaf, A.D. van Haarst, P. Fockens, H.C. Schoemaker, W.J. Krauwinkel and A.F. Cohen. The gastrointestinal passage and release of beclomethasone dipropionate from oral delivery systems in ileostomy volunteers. *Br J Clin Pharmacol* (1998) 46:3 207-214.
- 77 A.D. van Haarst, G.A. van 't Klooster, J.M. van Gerven, R.C. Schoemaker, J.C. van Oene, J. Burggraaf, M.C. Coene and A.F. Cohen. The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. *Clin Pharmacol Ther* (1998) 64:5 542-546.
- 76 J. Burggraaf, R.C. Schoemaker, I.J. Terpstra and A.F. Cohen. A phase I double-blind, placebo-controlled, single rising dose study to determine the safety, tolerability, and pharmacokinetics of oral YM934 in healthy male volunteers. *J Clin Pharmacol* (1998) 38:45-53
- 75 H.J. Gijsman, J.M.A. van Gerven, M.J. Tieleman, R.C. Schoemaker, M.S.M. Pieters, M.D. Ferrari, A.F. Cohen and G.M.J. van Kempen. Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. *J Clin Psychopharmacol* (1998) 18: 289-295.
- 74 J.G. Langendonk, H. Pijl, A.C. Toornvliet, J. Burggraaf, M. Fröhlich, R.C. Schoemaker, J. Doornbos, A.F. Cohen and A.E. Meinders. Circadian rhythm of plasma leptin levels in upper and lower body obese women: influence of body fat distribution and weight loss. *J Clin Endocrinol Metab* (1998) 83: 1706-1712.
- 73 O. Weijtens, R.C. Schoemaker, A.F. Cohen, F.P.H.T.M. Romijn, E.G.W.M. Lentjes, J. van Rooij and J.C. van Meurs. Dexamethasone concentrations in vitreous and serum after oral administration. *Am J Ophthalmol* (1998) 125: 673-679.
- 72 R.C. Schoemaker, J. Burggraaf and A.F. Cohen. Assessment of hepatic blood flow using continuous infusion of high clearance drugs. *Br J Clin Pharmacol* (1998) 45:463-469.
- 71 J. Burggraaf, R.C. Schoemaker, J.M. Kroon and A.F. Cohen. The influence of nifedipine and captopril on liver blood flow in healthy subjects. *Br J Clin Pharmacol* (1998) 45:447-451.
- 70 J.M.T. van Griensven, R.W. Koster, J. Burggraaf, L.G. Huisman, C. Kluft, R. Kroon, R.C. Schoemaker and A.F. Cohen. Effects of liver blood flow on the pharmacokinetics of tissue-type plasminogen activator (alteplase) during thrombolysis in patients with acute myocardial infarction. *Clin Pharmacol Ther* (1998) 63:39-47.
- 69 M. de Hoog, R.C. Schoemaker, J.W. Mouton and J.N. van den Anker. Tobramycin population pharmacokinetics in neonates. *Clin Pharmacol Ther* (1997) 62:392-399.
- 68 B. Tuk, J.J. Oberyé, M.S. Pieters, R.C. Schoemaker, B. Kemp, J. van Gerven, M. Danhof, H.A. Kamphuisen, A.F. Cohen, D.D. Breimer and C.C. Peck. Pharmacodynamics of temazepam in primary insomnia: assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement of sleep. *Clin Pharmacol Ther* (1997) 62:444-452.
- 67 J.M.T. van Griensven, R.W. Koster, G.R. Hopkins, H. Beier, W.A. Günzler, R. Kroon, R.C. Schoemaker and A.F. Cohen. Effect of changes in liver blood flow on the pharmacokinetics of saruplase in patients with acute myocardial infarction. *Thromb Haemost* (1997) 78:1015-1020.
- 66 J. Dingemans, J.M.A. van Gerven, R.C. Schoemaker, G. Roncari, J.J.L. Oberyé, M.F. van Oostenbruggen, J. Massarella, P. Segala, M. Zell and A.F. Cohen. Integrated pharmacokinetics and dynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. *Br J Clin Pharmacol* (1997) 44:477-486.
- 65 J.M.A. van Gerven, G. Roncari, R.C. Schoemaker, J. Massarella, P. Keesmaat, H. Kooyman, P. Heizmann, M. Zell, A.F. Cohen and J. Dingemans. Integrated pharmacokinetics and

- dynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects. *Br J Clin Pharmacol* (1997) 44:487-493.
- 64 G.J. Lycklama a Nijeholt, K. Burggraaf, M.N. Wasser, L.J. Schultze Kool, R.C. Schoemaker, A.F. Cohen and A. de Roos. Variability of splanchnic blood flow measurements using MR velocity mapping under fasting and post-prandial conditions - comparison with echo-Doppler (see comments). *J Hepatol* (1997) 26:298-304.
- 63 M.A.J. Tijssen, H.C. Schoemaker, P.J. Edelbroek, R.A.C. Roos, A.F. Cohen, J.G. van Dijk. The effects of clonazepam and vigabatrin in hyperekplexia. *J Neurol Sci* (1997) 149:63-67.
- 62 O. Weijtens, F.A. van der Sluijs, R.C. Schoemaker, E.G.W.M. Lentjes, A.F. Cohen, F.P.H.T.M. Romijn and J.C. van Meurs. Peribulbar corticosteroid injection: vitreal and serum concentrations after dexamethasone disodium phosphate injection. *Am J Ophthalmol* (1997) 123:358-363.
- 61 J.M.T. van Griensven, L.G.M. Huisman, T. Stuurman, G. Dooijewaard, R. Kroon, R.C. Schoemaker, K. Kluit and A.F. Cohen. Effects of increased liver blood flow on the kinetics and dynamics of recombinant tissue-type plasminogen activator. *Clin Pharmacol Ther* (1996) 60:504-511.
- 60 W.H. Visser, J. Burggraaf, L.M. Muller, R.C. Schoemaker, P.A. Fowler, A.F. Cohen and M.D. Ferrari. Pharmacokinetic and pharmacodynamic profiles of sumatriptan in migraine patients with headache recurrence or no response. *Clin Pharmacol Ther* (1996) 60:452-460.
- 59 J. Burggraaf, H.C. Schoemaker and A.F. Cohen. Assessment of changes in liver blood flow after food intake - comparison of ICG clearance and echo-Doppler. *Br J Clin Pharmacol* (1996) 42: 499-502.
- 58 J.M.A. van Gerven, R.C. Schoemaker, L.D. Jacobs, A. Reints, M.J. Ouwersloot-van der Meij, H.G.J. Hoedemaker and A.F. Cohen. Self-medication of a single headache episode with ketoprofen, ibuprofen or placebo, home-monitored with an electronic patient diary. *Br J Clin Pharmacol* (1996) 42: 475-481.
- 57 R.C. Schoemaker and A.F. Cohen. Estimating impossible curves using NONMEM. *Br J Clin Pharmacol* (1996) 42:283-290.
- 56 J.W. van der Pijl, N. Srivastava, J. Denouël, J. Burggraaf, R.C. Schoemaker, F.J. van der Woude and A.F. Cohen. Pharmacokinetics of the conventional and microemulsion formulations of cyclosporine in pancreas-kidney transplant recipients with gastroparesis. *Transplantation* (1996) 62:456-462.
- 55 M.E. Kars, H. Pijl, A.F. Cohen, M. Frohlich, H.C. Schoemaker, H.C.R. Brandenburg and A.E. Meinders. Specific stimulation of brain serotonin mediated neurotransmission by dexfenfluramide does not restore growth hormone responsiveness in obese women. *Clin Endocrinol (Oxf)* (1996) 44:541-546.
- 54 A.L. van Steveninck, R. Gieschke, R.C. Schoemaker, G. Roncari, B. Tuk, M.S.M. Pieters, D.D. Breimer and A.F. Cohen. Pharmacokinetic and pharmacodynamic interactions of zexil and diazepam with alcohol. *Br J Clin Pharmacol* (1996) 41: 565-573.
- 53 A.L. van Steveninck, A.E. Wallnöfer, R.C. Schoemaker, M.S.M. Pieters, M. Danhof and A.F. Cohen. A study of the effects of long term use on individual sensitivity to temazepam and lorazepam in a clinical population. *Br J Clin Pharmacol* (1997) 44:267-275.
- 52 J.N. van den Anker, B.J. van der Heijden, W.J.C. Hop, R.C. Schoemaker, H.M. Broerse, H.J. Neijens and R. de Groot. The effect of asphyxia on the pharmacokinetics of ceftazidime in the term newborn. *Pediatr Res* (1995) 38:808-811.

- 51 J.N. van den Anker, W.J.C. Hop, R.C. Schoemaker, B.J. van der Heijden, H.J. Neijens and R. de Groot. Ceftazidime pharmacokinetics in preterm infants: effect of postnatal age and postnatal exposure to indomethacin. *Br J Clin Pharmacol* (1995) 40:439-443.
- 50 J.N. van den Anker, R.C. Schoemaker, B.J. van der Heijden, H.M. Broerse, H.J. Neijens and R. de Groot. Once-daily versus twice-daily administration of ceftazidime in the preterm infant. *Antimicrob Agents Chemother* (1995) 39:2048-2050.
- 49 J.N. van den Anker, R.C. Schoemaker, W.C.J. Hop, B.J. van der Heijden, A. Weber, P.J.J. Sauer, H.J. Neijens and R. de Groot. Ceftazidime pharmacokinetics in preterm infants: effect of renal function and gestational age. *Clin Pharmacol Ther* (1995) 58:650-659.
- 48 H. Pijl, A.F. Cohen, R.J. Verkes, H.P.F. Koppeschaar, J.A. Iestra, H.C. Schoemaker, M. Frölich, W. Onkenhout and A.E. Meinders. Plasma amino acid ratios related to brain serotonin synthesis in response to food intake in bulimia nervosa. *Biol Psychiatry* (1995) 38:659-668.
- 47 J. van Rooij, G.H.D. van der Stegen, R.C. Schoemaker, C. Kroon, J. Burggraaf, L. Hollaar, T.F.F.P. Vroon, A.H.M. Smelt and A.F. Cohen. A placebo-controlled parallel study of the effect of two types of coffee oil on serum lipids and transaminases: identification of chemical substances involved in the cholesterol raising effect of coffee. *Am J Clin Nutr* (1995) 61:1277-1283.
- 46 A.A.M.J. Hollander, J. van Rooij, E.G.W.M. Lentjes, F. Arbouw, J.B. van Bree, R.C. Schoemaker, L.A. van Es, F.J. van der Woude and A.F. Cohen. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. *Clin Pharmacol Ther* (1995) 57:318-324.
- 45 J.M.T. van Griensven, K.J. Burggraaf, J. Gerlof, W.A. Günzler, H. Beier, R. Kroon, L.G.M. Huisman, R.C. Schoemaker, K. Kluft and A.F. Cohen. Effects of changing liver blood flow by exercise and food on kinetics and dynamics of saruplase. *Clin Pharmacol Ther* (1995) 57:381-389.
- 44 A.P. Aldenkamp, G. Baker, M.S.M. Pieters, H.C. Schoemaker, A.F. Cohen, S. Schwabe. The Neurotoxicity Scale: The validity of a patient-based scale, assessing neurotoxicity. *Epilepsy Res* (1995) 20:229-239.
- 43 J.J. Huisman-de Boer, J.N. van den Anker, M. Vogel, W.H.F. Goessens, R.C. Schoemaker and R. de Groot. Amoxicillin pharmacokinetics in preterm infants with gestational ages of less than 32 weeks. *Antimicrob Agents Chemother* (1995) 39:431-434.
- 42 J.M.T. van Griensven, R.C. Schoemaker, A.F. Cohen, H.G. Luus, M. Seibert-Grafe and H.-J. Röthig. Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril. *Eur J Clin Pharmacol* (1995) 47:513-518.
- 41 A.L. van Steveninck, H.C. Schoemaker, J. den Hartigh, M.S.M. Pieters, D.D. Breimer, and A.F. Cohen. Effects of intravenous temazepam. II. A study of the long-term reproducibility of pharmacokinetics, pharmacodynamics, and concentration-effect parameters. *Clin Pharmacol Ther* (1994) 55:546-555.
- 40 A.L. van Steveninck, H.C. Schoemaker, J. den Hartigh, J. Rijnkels, M.S.M. Pieters, D.D. Breimer, and A.F. Cohen. Effects of intravenous temazepam. I. Saccadic eye movements and electroencephalogram after fast and slow infusion to pseudo steady state. *Clin Pharmacol Ther* (1994) 55:535-545.
- 39 J. Burggraaf, H.C. Schoemaker, J.M. Kroon, L. Huisman, C. Kluft and A.F. Cohen. Influence of l-desamino-8-D-vasopressin on endogenous fibrinolysis, haemodynamics and liver blood flow in healthy subjects. *Clin Sci (Colch)* (1994) 86:497-503.

- 38 R.C. Schoemaker and H.C. van Houwelingen. Repeated measures for two within-subject factors; analysis and missing data solutions. *J Biopharm Stat* (1994) 4:173-188.
- 37 H. Pijl, H.P. Koppeschaar, A.F. Cohen, J.A. Iestra, H.C. Schoemaker, M. Fröhlich, W. Onkenhout and A.E. Meinders. Evidence for brain serotonin-mediated control of carbohydrate consumption in normal weight and obese humans. *Int J Obes Relat Metab Disord* (1993) 17:513-520.
- 36 A.E. Wallnöfer, J.M.T. van Griensven, H.C. Schoemaker, A.F. Cohen, W. Lambert, C. Kluft, P. Meijer and T. Kooistra. Effect of isotretinoin on endogenous tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor 1 (PAI-1) in humans. *Thromb Haemost* (1993) 70:1005-1008.
- 35 J.M.T. van Griensven, M. Seibert-Grafe, H.C. Schoemaker, M. Fröhlich and A.F. Cohen. The pharmacokinetic and pharmacodynamic interactions of ramipril with propranolol. *Eur J Clin Pharmacol* (1993) 45:255-260.
- 34 J. den Hartigh, C.G.J.M. Hilders, R.C. Schoemaker, J.H. Hulshof, A.F. Cohen and P. Vermeij. Tinnitus suppression by intravenous lidocaine in relation to its plasma concentration. *Clin Pharmacol Ther* (1993) 54:415-420.
- 33 A.L. van Steveninck, R. Gieschke, H.C. Schoemaker, M.S.M. Pieters, J.M. Kroon, D.D. Breimer and A.F. Cohen. Pharmacodynamic interactions of diazepam and intravenous alcohol at pseudo steady state. *Psychopharmacology (Berl)* (1993) 110:471-478.
- 32 A.L. van Steveninck, J.W. Mandema, B. Tuk, J.G. van Dijk, H.C. Schoemaker, M. Danhof and A.F. Cohen. A comparison of the concentration effect relationships of midazolam for EEG derived parameters and saccadic peak velocity. *Br J Clin Pharmacol* (1993) 36:109-115.
- 31 A.L. van Steveninck, M.S.M. Pieters, H.C. Schoemaker, D.D. Breimer and A.F. Cohen. CNS related performance and haemodynamics of metoprolol Oros and propranolol after single and 3 days dosing in healthy volunteers. *Br J Clin Pharmacol* (1993) 35:114-120.
- 30 P.A. Soons, T.M.T. Mulders, E. Uchida, H.C. Schoemaker, A.F. Cohen and D.D. Breimer. Stereoselective pharmacokinetics of oral felodipine and nitrendipine in healthy subjects: correlations with nifedipine pharmacokinetics. *Eur J Clin Pharmacol* (1993) 44:163-169.
- 29 J. van Rooij, H.C. Schoemaker, R. Bruno, J.F. Reinhoudt, D.D. Breimer and A.F. Cohen. Cimetidine does not influence the metabolism of the H1 receptor antagonist ebastine to its active metabolite carebastine. *Br J Clin Pharmacol* (1993) 35:661-663.
- 28 T.M.T. Mulders, V. Venizelos, R. Schoemaker, A.F. Cohen, D.D. Breimer and G.J. Mulder. Characterization of glutathione conjugation in humans: stereoselectivity in plasma elimination pharmacokinetics and urinary excretion of (R) and (S) 2-bromoisovalerylurea in healthy volunteers. *Clin Pharmacol Ther* (1993) 53:49-58.
- 27 A.F. Cohen, R. Kroon, H.C. Schoemaker, D.D. Breimer, A. van Vliet Verbeek and H.C. Brandenburg. The bioavailability of digoxin from three oral formulations measured by a specific HPLC assay. *Br J Clin Pharmacol* (1993) 35:136-142.
- 26 A. de Boer, C. Kluft, F.J. Kasper, J.M. Kroon, H.C. Schoemaker, D.D. Breimer, P.A. Soons and A.F. Cohen. Interaction study between nifedipine and recombinant tissue type plasminogen activator in healthy subjects. *Br J Clin Pharmacol* (1993) 36:99-104.
- 25 A.L. van Steveninck, S. Verver, H.C. Schoemaker, M.S.M. Pieters, R. Kroon, D.D. Breimer and A.F. Cohen. Effects of temazepam on saccadic eye movements: concentration effect relationships in individual volunteers. *Clin Pharmacol Ther* (1992) 52:402-408.

- 24 P.A. Soons, H.C. Schoemaker, A.F. Cohen and D.D. Breimer. Intraindividual variability in nifedipine pharmacokinetics and effects in healthy subjects. *J Clin Pharmacol* (1992) 32:324-331.
- 23 M.S.M. Pieters, A. Jennekens Schinkel, H.C. Schoemaker and A.F. Cohen. Self selection for personality variables among healthy volunteers. *Br J Clin Pharmacol* (1992) 33:101-106.
- 22 J.W.M. Krulder, A. de Boer, A.M.H.P. van den Besselaar, A.F. Cohen, H.C. Schoemaker, E. Briet and A.E. Meinders. Diurnal rhythm in anticoagulant effect of heparin during a low dose constant rate infusion. A study in healthy volunteers. *Thromb Haemost* (1992) 68:30-32.
- 21 C. Kroon, W.R. ten Hove, A. de Boer, J.M. Kroon, J.M.J. van der Pol, E.J. Harthoorn Lasthuizen, H.C. Schoemaker, F.J.M. van der Meer and A.F. Cohen. Highly variable anticoagulant response after subcutaneous administration of high dose (12,500 iu) heparin in patients with myocardial infarction and healthy volunteers. *Circulation* (1992) 86:1370-1375. (With Editorial Comment)
- 20 A.F. Cohen, J.K. Boeijinga, P.M.M. van Haard, R.C. Schoemaker and A. van Vliet Verbeek. Gastrointestinal blood loss after non steroidal anti inflammatory drugs. Measurement by selective determination of faecal porphyrins. *Br J Clin Pharmacol* (1992) 33:33-38.
- 19 A. de Boer, J.M. Kroon, C. Kroon, A. van Vliet, H.C. Schoemaker, D.D. Breimer, S. Donoghue and A.F. Cohen. Pronounced effects of the combination of a new thromboxane antagonist (GR32191) and heparin on bleeding time in man. *Thromb Haemost* (1992) 68:24-29.
- 18 A. Boer, C. Kluft, J.M. Kroon, F.J. Kasper, H.C. Schoemaker, J. Pruis, D.D. Breimer, P.A. Soons, J.J. Emeis and A.F. Cohen. Liver blood flow as a major determinant of the clearance of recombinant human tissue type plasminogen activator. *Thromb Haemost* (1992) 67:83-87.
- 17 A.L. van Steveninck, H.C. Schoemaker, M.S.M. Pieters, R. Kroon, D.D. Breimer and A.F. Cohen. A comparison of the sensitivities of adaptive tracking, eye movement analysis and visual analog lines to the effects of incremental doses of temazepam in healthy volunteers. *Clin Pharmacol Ther* (1991) 50:172-180.
- 16 P.A. Soons, B.A.P.M. Vogels, M.C.M. Roosemalen, H.C. Schoemaker, E. Uchida, B. Edgar, J. Lundahl, A.F. Cohen and D.D. Breimer. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. *Clin Pharmacol Ther* (1991) 50:394-403.
- 15 C. Kroon, A. de Boer, J.M. Kroon, H.C. Schoemaker, F.J.M. van den Meer and A.F. Cohen. Influence of skinfold thickness on heparin absorption. *Lancet* (1991) 337:945-946.
- 14 A.F. Cohen, R. Kroon, R. Schoemaker, H. Hoogkamer and A. van Vliet. Influence of gastric acidity on the bioavailability of digoxin. *Ann Intern Med* (1991) 115:540-545.
- 13 C. Kroon, A. de Boer, J.F.W. Hoogkamer, H.C. Schoemaker, F.J.M. van der Meer, P.M. Edelbroek and A.F. Cohen. Detection of drug interactions with single dose acenocoumarol: new screening method? *Int J Clin Pharmacol Ther Toxicol* (1990) 28:355-360.
- 12 A.F. Cohen, M.A. van Hall, J. van Harten, R.C. Schoemaker, P. Johansson, D.D. Breimer, R. Visser and B. Edgar. The influence of infusion rate on the hemodynamic effects of felodipine. *Clin Pharmacol Ther* (1990) 48:309-317.
- 11 G. van den Berg, F. van Steveninck, J.M. Gubbens Stibbe, H.C. Schoemaker, A.G. de Boer and A.F. Cohen. Influence of food on the bioavailability of metoprolol from an OROS system; a study in healthy volunteers. *Eur J Clin Pharmacol* (1990) 39:315-316.
- 10 J.M. Swartjes, H.P. van Geijn, R. Mantel and H.C. Schoemaker. Quantitated fetal heart rhythm at 20, 32 and 38 weeks of gestation and dependence on rest-activity patterns. *Early Hum Dev* (1992) 28:27-36.

- 9 J.M. Swartjes, H.P. van Geijn, H. Meinardi, M. van Alphen and H.C. Schoemaker. Fetal rest-activity cycles and chronic exposure to anti-epileptic drugs. *Epilepsia* (1991) 32:722-728.
- 8 J.M. Swartjes, H.P. van Geijn, R. Mantel, E.E. van Woerden and H.C. Schoemaker. Coincidence of behavioural state parameters in the human fetus at three gestational ages. *Early Hum Dev* (1990) 23:75-83.
- 7 D.D.M. Braat, R. Schoemaker and J. Schoemaker. Life table analysis of fecundity in intravenously gonadotropin-releasing hormone-treated patients with normogonadotropic and hypogonadotropic amenorrhea. *Fertil Steril* (1991) 55:266-271.
- 6 J. Schoemaker, H. Schoemaker, G. Berkhout and H.C. Schoemaker. Pulsatile Luteinizing Hormone secretion in hypothalamic amenorrhea. *Advances in Gynecological Endocrinology (Proceedings of the 1st Congress of the International Society of Gynecological Endocrinology)*, A.R. Genazzani, F. Petraglia, A. Volpe, F. Facchinetti (Eds.). The Parthenon Publishing Group, Carnforth, Lancs. England (1989) 1:43-50.
- 5 M.M. van Weissenbruch, H.C. Schoemaker, H.A. Drexhage and J. Schoemaker. Pharmacodynamics of human menopausal gonadotrophin (HMG) and follicle-stimulating hormone (FSH). The importance of the FSH concentration in initiating follicular growth in polycystic ovary-like disease. *Hum Reprod* (1993) 8:813-821.
- 4 J.M.B. Wennink, H.A. Delamarre-van de Waal, R. Schoemaker, G. Blaauw, C. van den Braken and J. Schoemaker. Growth Hormone secretion patterns in relation to LH and estradiol throughout female puberty. *Acta Endocrinol (Copenh)* (1991) 124:129-135.
- 3 J.M.B. Wennink, H.A. Delamarre-van de Waal, R. Schoemaker G. Blaauw, C. van den Braken and J. Schoemaker. Growth Hormone secretion patterns in relation to LH and testosterone secretion throughout normal male puberty. *Acta Endocrinol (Copenh)* (1990) 123:263-270.
- 2 J.M.B. Wennink, H.A. Delamarre-van de Waal, R. Schoemaker, H. Schoemaker and J. Schoemaker. Luteinizing Hormone and Follicle Stimulating Hormone secretion patterns in girls throughout puberty, measured using a highly sensitive immunoradiometric assay. *Clin Endocrinol (Oxf)* (1990) 33:333-344.
- 1 J.M.B. Wennink, H.A. Delamarre-van de Waal, R. Schoemaker, H. Schoemaker and J. Schoemaker. Luteinizing Hormone and Follicle Stimulating Hormone secretion patterns in boys throughout puberty, measured using a highly sensitive immunoradiometric assay. *Clin Endocrinol (Oxf)* (1989) 31:551-564.